Ascendis Pharma ADR (NQ: ASND )
89.75 +1.29 (+1.46%) Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Headline News about Ascendis Pharma ADR
Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism
November 14, 2022
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
October 20, 2022
Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid...
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
August 11, 2022
Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the...
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
March 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following